Malignant Neoplasm of Unknown Primary — Trials

Malignant Neoplasm of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,163
Recruiting: 2,261
Ph III recruiting: 270
Growth YoY: +12.5%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,895)

clinicaltrialsPublishedShowing 5,851–5,900 of 6,228 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01118845	Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma	completed	Phase 2	63	SymBio PharmaceuticalsINDUSTRY	2	Jul 4, 2013	clinicaltrials
NCT00459043	Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck	completed	Phase 2	30	Dana-Farber Cancer InstituteOTHER	1	Jul 3, 2013	clinicaltrials